This webcast features: Sarathi Vijay Boddapati, PhD, Associate Director, Formulation and Drug Product Development, Catalent Cell and Gene Therapy Formulation studies for gene therapy products are currently limited in scope and revolve around gathering stability data at frozen storage conditions. A systematic approach towards understanding degradation mechanisms followed by buffer and excipient selection is required. Catalent Cell & Gene Therapy is working towards an approach for gathering product knowledge and establishing formulation selection criteria using traditional/routine techniques that are historically…
Thursday, March 25, 2021 Daily Archives
Oravax launches to advance oral COVID-19 vaccines
Oramed Pharmaceuticals and Prema Biotech have formed Oravax Medical, a joint venture focused on developing oral COVID-19 vaccines. The joint venture company, Oravax, will use India-based Premas Biotech’s vaccine technology combined with Israel-based Oramed’s POD oral delivery technology. Oravax’s COVID-19 vaccine candidate is a virus like particle (VLP) that targets three structural proteins, which has the potential to provide protection against emerging variants of coronavirus. Furthermore, the oral administration of the vaccine may enable easier distribution and large-scale inoculation without…
Curi Bio receives $6m funding boost for human stem cell platforms
The financing will support Curi Bio’s 2D and 3D platforms, which aim to improve the predictivity of human stem cell-derived tissue for drug discovery. Curi Bio’s platform technologies use human iPSC-derived cells, tissue-specific biosystems, and AI-enabled data analytics to help accelerate the discovery of therapeutics. The Series A financing round, led by Dynamk Capital, will help grow the business and validate the tech to show the need for predictive and mature human stem cell platforms to close the gap between…